Pharma Ads Enter the Exam Room Through Your Doctor's EHR

NEWARK, N.J. – January 22, 2026 – In a move that signals a new frontier for pharmaceutical marketing, technology firm PulsePoint today announced an exclusive partnership with Flora Health, effectively opening a direct, automated advertising channel into the electronic health records (EHRs) used by doctors and nurses during patient care.

The strategic alliance makes PulsePoint the sole demand-side platform (DSP) able to programmatically sell advertising space within the network of health systems integrated by Flora Health. This allows life sciences companies to place targeted messages directly into the digital workflow of healthcare professionals (HCPs) at the very moments they are reviewing patient charts, diagnosing conditions, and prescribing treatments.

A New Era of Omnichannel Marketing

For years, the holy grail for healthcare marketers has been to reach physicians at the point of care, a space traditionally fragmented and difficult to access at scale. This partnership aims to shatter those limitations. By integrating programmatic technology—the automated buying and selling of digital advertising—with the EHR environment, the two companies are creating a powerful, unified platform.

"This strategic partnership closes one of the most critical gaps in omnichannel HCP marketing by unlocking access to scalable EHR programmatic inventory," said Keith Matt, Group Vice President of Sales at PulsePoint. "For the first time, our pharma partners can truly orchestrate programmatic EHR at scale alongside every other channel, all within a single platform."

The significance lies in moving beyond the siloed approach where EHR advertising was a separate, manually managed campaign. Now, brands can apply the sophisticated tools of programmatic advertising—such as audience targeting, frequency capping, and real-time optimization—to their in-EHR campaigns, aligning them with their broader media strategy. With HCPs spending an average of four to five hours per day within these digital systems, the platform offers unprecedented access to an engaged, professional audience at the moment of decision.

Flora Health, which acts as a systems integrator connecting various technologies within health systems, provides the crucial gateway. "Our work with PulsePoint extends that value tip to tail, giving partners the ability to activate these moments at scale with consistency, confidence, and fidelity across diverse health system environments," stated Russell Grimaldi, Chief Commercial Officer at Flora Health.

The Competitive Race for Physician Engagement

While the announcement touts exclusivity, it’s important to understand the context of the competitive landscape. The exclusivity applies specifically to Flora Health's integrated network of health systems. PulsePoint is not the only company operating in this space. Competitors like Veradigm Digital Health Media, which is certified by the Point of Care Marketing Association (POCMA), also offer programmatic EHR advertising directly through their own extensive networks. Other platforms like OptimizeRx and WebMD Ignite also provide various forms of programmatic access to HCPs.

The industry has long been moving toward breaking down data silos to create more integrated marketing ecosystems. This deal represents a significant strategic maneuver by PulsePoint to consolidate access through a key network, giving it a distinct advantage. By securing this exclusive arrangement, PulsePoint can offer its clients a unique, streamlined path to a specific segment of the EHR market, potentially forcing competitors and brands to navigate a more complex patchwork of providers to achieve similar reach.

The Doctor's View: Enhancement or Disruption?

The introduction of commercial messaging into the clinical sanctum of the EHR is a double-edged sword. On one hand, proponents argue that relevant, timely information can enhance clinical decision-making. A well-placed message about a new therapy, patient co-pay assistance program, or important dosing update could, in theory, support better care.

Indeed, some data suggests physicians are open to it; a 2023 survey found that 68% of physicians considered EHRs a top channel for accessing brand information. When the content is perceived as valuable and non-intrusive, it can be viewed as a helpful resource rather than a distraction.

However, the risks of disruption and physician burnout are substantial. EHR systems are already a major source of frustration for many clinicians due to clunky interfaces and administrative burden. The addition of advertisements, no matter how relevant, could contribute to "alert fatigue" and information overload, potentially distracting from critical patient data.

The American Medical Association (AMA) has voiced caution, expressing opposition to "direct-to-prescriber pharmaceutical and promotional content in EHRs" unless it adheres to strict guidelines. The organization has called for further study on the effects of such advertising on prescribing habits, patient safety, and healthcare costs, reflecting deep-seated concerns within the medical community about the commercialization of the clinical workspace.

Navigating a Regulatory Minefield

This new advertising channel operates within one of the most heavily regulated sectors. Any company placing ads in an EHR must navigate a complex web of federal and state laws. The Health Insurance Portability and Accountability Act (HIPAA) strictly governs the use of Protected Health Information (PHI) for marketing, typically requiring explicit patient authorization. While these platforms are built to use de-identified or aggregated data for targeting, the line can be thin, and recent HHS guidance on tracking technologies has increased scrutiny.

Furthermore, the Food and Drug Administration (FDA) regulates the content of all pharmaceutical advertising, mandating that it be truthful, balanced, and free of off-label promotion. Any ad displayed must include a fair balance of risk and benefit information. Finally, the Anti-Kickback Statute (AKS) prohibits any form of remuneration to induce referrals or prescriptions, meaning the financial structures of these partnerships must be carefully designed to avoid any appearance of paying for prescriptions.

The rise of state-level privacy laws adds another layer of complexity, creating a patchwork of compliance requirements that demand constant vigilance. Success in this space depends not only on technological prowess but on an unwavering commitment to ethical standards and regulatory adherence.

The Quest for Better Patient Outcomes

The ultimate justification for in-workflow advertising is the claim that it drives better patient outcomes. The theoretical link is clear: a more informed physician makes better prescribing decisions, and providing access to patient support programs can improve medication adherence. Companies in this space often point to proxy metrics like "script lift"—a measurable increase in prescriptions for an advertised drug—as evidence of their impact. Data from various platforms show that exposure to in-EHR media correlates with higher prescribing rates.

However, the leap from script lift to a definitive improvement in a patient's long-term health is one that is not yet fully substantiated by independent research. As the AMA noted in a 2021 report, direct evidence linking this form of advertising to better patient outcomes is "noticeably lacking." While a new prescription is a necessary first step, it is not the sole determinant of a patient's health journey. The industry and healthcare providers alike will be watching closely to see if the promise of enhanced decision-making can be realized without compromising the integrity of patient care.